Horizon / Plein textes La base de ressources documentaires de l'IRD

IRD

 

Publications des scientifiques de l'IRD

Denoeud Ndam Lise, Clément M. C., Briand Valérie, Akakpo J., Agossou V. K., Atadokpédé F., Dossou-Gbété L., Komongui D. G., Afangnihoun A., Girard P. M., Zannou D. M., Cot Michel. (2012). Tolerability of mefloquine intermittent preventive treatment for malaria in HIV-infected pregnant women in Benin. Jaids-Journal of Acquired Immune Deficiency Syndromes, 61 (1), 64-72. ISSN 1525-4135

Accès réservé (Intranet IRD) Demander le PDF

Lien direct chez l'éditeur doi:10.1097/QAI.0b013e3182615a58

Titre
Tolerability of mefloquine intermittent preventive treatment for malaria in HIV-infected pregnant women in Benin
Année de publication2012
Type de documentArticle référencé dans le Web of Science WOS:000308352000015
AuteursDenoeud Ndam Lise, Clément M. C., Briand Valérie, Akakpo J., Agossou V. K., Atadokpédé F., Dossou-Gbété L., Komongui D. G., Afangnihoun A., Girard P. M., Zannou D. M., Cot Michel.
SourceJaids-Journal of Acquired Immune Deficiency Syndromes, 2012, 61 (1), p. 64-72. ISSN 1525-4135
RésuméObjective: To investigate the tolerability of mefloquine intermittent preventive treatment (MQ IPTp) for malaria in HIV-infected pregnant women compared with HIV-negative women. Design: Prospective cohort study comparing samples of HIV-negative and HIV- infected pregnant women from 2 clinical trials conducted in Benin. Methods: One hundred and three HIV-infected women from the ongoing PACOME trial were compared with 421 HIV-negative women from a former trial, both trials aiming to evaluate the efficacy and tolerability of MQ IPTp, administered at the dose of 15 mg/kg. Descriptive analysis compared the proportion of women reporting at least 1 adverse reaction, according to HIV status. Multilevel logistic regression identified factors associated with the probability of reporting an adverse reaction for each MQ intake. Results: Dizziness and vomiting were the most frequent adverse reactions. Adverse reactions were less frequent in HIV-infected women (65% versus 78%, P = 0.009). In multilevel analysis, HIV infection [odds ratio (OR) = 0.23, 95% confidence interval (CI) = 0.08 to 0.61] decreased the risk for adverse reactions, whereas detectable viral load (OR = 2.46, 95% CI = 1.07 to 5.66), first intake (versus further intakes, OR = 5.26, 95% CI = 3.70 to 7.14), older age (OR = 1.62, 95% CI = 1.13 to 2.32), and higher education level (OR = 1.71, 95% CI = 1.12 to 2.61) increased the risk. Moderate and severe adverse reactions were more frequent when antiretrovirals were started concomitantly with a MQ intake. Conclusions: This study provides reassuring data on the use of MQ IPTp in HIV-infected pregnant women. However frequent, adverse reactions remained moderate and did not impair adherence to MQ IPTp. In this high-risk group, MQ might be an acceptable alternative in case sulfadoxine-pyrimethamine loses its efficacy for intermittent preventive treatment.
Plan de classementEntomologie médicale / Parasitologie / Virologie [052] ; Santé : généralités [050]
LocalisationFonds IRD [F B010057157]
Identifiant IRDfdi:010057157
Lien permanenthttp://www.documentation.ird.fr/hor/fdi:010057157

Export des données

Disponibilité des documents

Télechargment fichier PDF téléchargeable

Lien sur le Web lien chez l'éditeur

Accès réservé en accès réservé

HAL en libre accès sur HAL


Accès aux documents originaux :

Le FDI est labellisé CollEx

Accès direct

Bureau du chercheur

Site de la documentation

Espace intranet IST (accès réservé)

Suivi des publications IRD (accès réservé)

Mentions légales

Services Horizon

Poser une question

Consulter l'aide en ligne

Déposer une publication (accès réservé)

S'abonner au flux RSS

Voir les tableaux chronologiques et thématiques

Centres de documentation

Bondy

Montpellier (centre IRD)

Montpellier (MSE)

Cayenne

Nouméa

Papeete

Abidjan

Dakar

Niamey

Ouagadougou

Tunis

La Paz

Quito